Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A mutation in yeast topoisomerase II that confers hypersensitivity to multiple classes of topoisomerase II poisons.

The Journal of biological chemistry - 17 Mar 2000

Dong J, Walker J, Nitiss J L

Abstract excerpt

A mutation was constructed in the CAP homology domain of yeast topoisomerase II that resulted in hypersensitivity to the intercalating agent N-[4-(9-acridinylamino)-3-methoxy-phenyl]methanesulfonamide and the fluoroquinolone 6, 8-difluoro-7-(4'-hydroxyphenyl)-1-cyclopropyl-4-quinolone-3-carboxyli c acid, but not to etoposide. This mutation, which changes threonine at position 744 to proline, also confers...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Amsacrine
Share to Anti-Infective Agents
Share to DNA Topoisomerases, Type II

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Dose-Response Relationship, Drug

Share to Enzyme Inhibitors

Share to Eukaryotic Cells

Share to Fluoroquinolones

Share to Topoisomerase II Inhibitors

Source

Identifiers

PMID: 10713116
DOI: 10.1074/jbc.275.11.7980

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A mutation in yeast topoisomerase II that confers hypersensitivity to multiple classes of topoisomerase II poisons.PMID 10713116Read ↗

Isolation and characterization of mAMSA-hypersensitive mutants. Cytotoxicity of Top2 covalent complexes containing DNA single strand breaks.Semantic proximity Read ↗

A Yeast-Based Screening System for Differential Identification of Poison Inhibitors and Catalytic Inhibitors of Human Topoisomerase ISemantic proximity Read ↗

Increased sensitivity to quinolone antibacterials can be engineered in human topoisomerase IIalpha by selective mutagenesis.Semantic proximity Read ↗

Interaction model for anthracycline activity against DNA topoisomerase II.Semantic proximity Read ↗

DNA Topoisomerases and Their Poisoning by Anticancer and Antibacterial DrugsSemantic proximity Read ↗

CDC45 and DPB11 are required for processive DNA replication and resistance to DNA topoisomerase I-mediated DNA damage.Semantic proximity Read ↗

Using yeast to study resistance to topoisomerase II-targeting drugs.Semantic proximity Read ↗

Mutation of Gly721 alters DNA topoisomerase I active site architecture and sensitivity to camptothecin.Semantic proximity Read ↗

Yeast topoisomerase II mutants resistant to anti-topoisomerase agents: identification and characterization of new yeast topoisomerase II mutants selected for resistance to etoposide.Semantic proximity Read ↗

The top2-5 mutant of yeast topoisomerase II encodes an enzyme resistant to etoposide and amsacrine.Semantic proximity Read ↗

Human DNA topoisomerase IIalpha-dependent DNA cleavage and yeast cell killing by anthracycline analogues.Semantic proximity Read ↗

Mutation P732L in human DNA topoisomerase IIbeta abolishes DNA cleavage in the presence of calcium and confers drug resistance.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.